Rafferty Asset Management’s Avidity Biosciences RNA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.6M | Sell |
126,882
-17,935
| -12% | -$509K | 0.01% | 465 |
|
|
2025
Q1 | $4.27M | Sell |
144,817
-32,167
| -18% | -$950K | 0.02% | 403 |
|
|
2024
Q4 | $5.15M | Sell |
176,984
-22,381
| -11% | -$651K | 0.02% | 411 |
|
|
2024
Q3 | $9.16M | Buy |
199,365
+78,808
| +65% | +$3.62M | 0.03% | 298 |
|
|
2024
Q2 | $4.92M | Sell |
120,557
-146,575
| -55% | -$5.99M | 0.02% | 419 |
|
|
2024
Q1 | $6.82M | Sell |
267,132
-3,027
| -1% | -$77.2K | 0.03% | 385 |
|
|
2023
Q4 | $2.44M | Sell |
270,159
-118,923
| -31% | -$1.08M | 0.01% | 625 |
|
|
2023
Q3 | $2.48M | Sell |
389,082
-218,428
| -36% | -$1.39M | 0.01% | 552 |
|
|
2023
Q2 | $6.74M | Buy |
607,510
+226,589
| +59% | +$2.51M | 0.04% | 351 |
|
|
2023
Q1 | $5.85M | Buy |
380,921
+63,978
| +20% | +$982K | 0.04% | 348 |
|
|
2022
Q4 | $7.03M | Buy |
316,943
+181,861
| +135% | +$4.04M | 0.06% | 299 |
|
|
2022
Q3 | $2.21M | Buy |
135,082
+90,108
| +200% | +$1.47M | 0.02% | 487 |
|
|
2022
Q2 | $653K | Sell |
44,974
-32,853
| -42% | -$477K | 0.01% | 760 |
|
|
2022
Q1 | $1.44M | Buy |
77,827
+13,620
| +21% | +$251K | 0.01% | 701 |
|
|
2021
Q4 | $1.53M | Buy |
64,207
+22,726
| +55% | +$540K | 0.01% | 751 |
|
|
2021
Q3 | $1.02M | Sell |
41,481
-6,715
| -14% | -$165K | 0.01% | 809 |
|
|
2021
Q2 | $1.19M | Sell |
48,196
-12,508
| -21% | -$309K | 0.01% | 824 |
|
|
2021
Q1 | $1.32M | Buy |
+60,704
| New | +$1.32M | 0.01% | 708 |
|